CompBrief BY VELARION

Companies Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics CEO salary & total pay, FY2025: $4.7M

Aldeyra Therapeutics (ALDX) CEO salary, fiscal 2025: Todd Brady was paid a salary of $700,000 and $4,704,179 in total compensation. Free brief. Every figure links to the company’s own filing.

Velarion Intel: free for 3 days, no card →

Email me Aldeyra Therapeutics, Inc.’s executive pay brief as a PDF

You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.

After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.

Also free: The Pay Desk, the weekly executive pay briefing.

Todd Brady's complete compensation dossier

A PDF and a CSV sent to your email: Todd Brady's pay in every fiscal year Aldeyra Therapeutics, Inc. reported it, line by line, with Todd Brady's equity grants and Aldeyra Therapeutics, Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.

One-time report. No refunds.

See an example →
CEO total pay$4,704,179CEO Todd Brady · source
Say-on-pay support80.79%Latest vote · source

CEO pay, last three years

  • $3,684,651FY2023
  • $3,931,645FY2024
  • $4,704,179FY2025

CEO total pay was $4,704,179 in fiscal 2025, up from $3,931,645 in fiscal 2024.

FY2025: salary $700,000 · bonus $0 · stock awards $0 · option awards $3,801,379

Executives and directors

Frequently asked questions

Who was the highest-paid executive at Aldeyra Therapeutics, Inc. in fiscal 2025?
As disclosed, Todd Brady (President and Chief Executive Officer) was the highest-paid executive at Aldeyra Therapeutics, Inc. in fiscal 2025, with total compensation of $4,704,179.
How did shareholders vote on Aldeyra Therapeutics, Inc.'s executive compensation?
As disclosed, 80.79% of shareholders supported Aldeyra Therapeutics, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Aldeyra Therapeutics, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Aldeyra Therapeutics, Inc. reported total board compensation of $320,222 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table
Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Todd Brady$700,000$0$0$3,801,379$189,000$0$14,000$4,704,179
President and Chief Executive Officer
Stephen Machatha400,000——950,342——101,8001,452,142
Chief Development Officer
Michael Alfieri000000243,994245,963
Principal Financial Officer and Principal Accounting Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Todd Brady$4,704,179$3,931,645$3,684,651↑ +772,534
Stephen Machatha1,452,1421,688,3811,593,108↓ −236,239
Michael Alfieri245,963111,650—↑ +134,313

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

The executive compensation program is designed to ensure consistency with short-term and long-term goals, attract and retain talent, and align the interests of named executive officers with stockholders by providing compensation based on the achievement of pre-established corporate financial goals. The program emphasizes a pay-for-performance philosophy where variable compensation and long-term equity incentives represent over 75% of target direct compensation.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantPearl Meyer & Partners, LLC
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
Equity grants and outstanding awards

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Todd BradyOPTION2025-03-04——809,710—$3,801,379
Stephen MachathaOPTION2025-03-04——202,427—950,342

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Todd Brady$0$0$3,801,3790.0%
Stephen Machatha00950,3420.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardExercisableShares unvestedExercise priceMarket value unvested
Stephen MachathaOption244,7915,2094.52—
Stephen MachathaRSU—16,099—83,393
Stephen MachathaRSU—46,402—240,362
Stephen MachathaOption160,60459,6546.76—
Stephen MachathaOption194,278211,1723.62—
Stephen MachathaOption46,389156,0386.17—
Stephen MachathaOption35,000—4.6—
Stephen MachathaOption26,200—5.25—
Stephen MachathaOption45,573—8.35—
Stephen MachathaOption63,000—8.05—
Stephen MachathaOption135,560—3.78—
Stephen MachathaOption116,201—11.71—
Todd BradyOption244,7915,2094.52—
Todd BradyRSU—62,500—323,750
Todd BradyOption182,29167,7096.76—
Todd BradyRSU—119,375—618,363
Todd BradyOption518,075563,1263.62—
Todd BradyOption185,558624,1526.17—
Todd BradyOption250,000—4.59—
Todd BradyOption250,000—5.1—
Todd BradyOption217,293—8.6—
Todd BradyOption250,000—8.05—
Todd BradyOption250,000—3.78—
Todd BradyOption250,000—11.71—
Director compensation
DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Richard H. Douglas, Ph.DIndependent · Board Chair · Nominating/Corporate Governance · Not standing for re-election$61,750—$163,466——$225,216
Martin J. Joyce, M.B.AIndependent · Audit (Chair) · Nominating/Corporate Governance · Not standing for re-election49,250—148,469——197,719
Gary M. Phillips, M.DIndependent · Audit · Compensation (Chair) · Not standing for re-election48,750—147,468——196,218
Ben R. Bronstein, M.DIndependent · Audit · Nominating/Corporate Governance (Chair) · Not standing for re-election47,250—145,469——192,719
Neal S. Walker, D.OIndependent · Compensation · Not standing for re-election42,500—134,972——177,472
Nancy B. Miller-RichIndependent · Compensation · Not standing for re-election42,500—134,972——177,472
William D. ClarkIndependent · Not standing for re-election28,222—134,237——162,459

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer$130,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)7,500 / 5,000 / 3,500
Stock ownership guideline—

Total cost of the board

ComponentFY2025
Cash retainers and fees$320,222
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$320,222

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Aldeyra Therapeutics as a peer

Companies that benchmark against ALDX

2 companies name ALDX as a compensation peer

Each company listed discloses ALDX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ALDX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Aldeyra Therapeutics, Inc.2025Todd Brady$700,000$0$3,801,379$189,000$4,704,179

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Say-on-pay history and pay ratio
Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-0919,477,5044,543,22187,13880.79%Passed
20252025-06-1018,847,6207,919,279181,46569.94%Passed
20242024-06-0431,493,3192,862,040126,60691.33%Passed
20232023-06-3027,710,251646,06057,32397.52%Passed
20222022-06-0723,243,9093,179,90065,33487.75%Passed
20212021-06-0820,666,4315,734,541126,45877.91%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting yearMeeting dateApproval — company’s computation
20262026-06-0980.79%a
20252025-06-1069.94%b
20242024-06-0491.33%c

a. Approved under the standard stated in the filing — “Required Vote and Recommendation of the Board of Directors for Proposal 3 A " FOR " vote from the holders of a majority of the shares of common stock present in person or represented by proxy at the Annual Meeting is required to approve, on a non-binding, advisory basis, the compensation of our named executive officers. || Abstentions: Abstentions and broker non-votes will have the same effect as a vote "Against" this matter.”.

b. Approved under the standard stated in the filing — “Required Vote and Recommendation of the Board of Directors for Proposal 3 A " FOR " vote from the holders of a majority of the shares of common stock present in person or represented by proxy at the Annual Meeting is required to approve, on a non-binding, advisory basis, the compensation of our named executive officers. || Abstentions: Abstentions and broker non-votes will have the same effect as a vote "Against" this matter.”.

c. Approved under the standard stated in the filing — “Required Vote and Recommendation of the Board of Directors for Proposal 3 A " FOR " vote from the holders of a majority of the shares of common stock present in person or represented by proxy at the Annual Meeting is required to approve, on a non-binding, advisory basis, the compensation of our named executive officers. || Abstentions: Abstentions and broker non-votes will have the same effect as a vote "Against" this matter.”.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Todd BradyDirector2026-06-03A250,000$2$418,450CommonForm 4 ↗
William D. ClarkDirector2026-06-09A2,32300Derivative, Class A CommonForm 4 ↗
William D. ClarkDirector2026-06-09A70,00000Derivative, Class A CommonForm 4 ↗
Nancy B. Miller-RichDirector2026-06-09A3,31800Derivative, Class A CommonForm 4 ↗
Nancy B. Miller-RichDirector2026-06-09A70,00000Derivative, Class A CommonForm 4 ↗
Darlene M. Deptula-HicksDirector2026-06-09A9,75600Derivative, Class A CommonForm 4 ↗
Darlene M. Deptula-HicksDirector2026-06-09A84,55700Derivative, Class A CommonForm 4 ↗
Ben BronsteinDirector2026-06-09A4,97700Derivative, Class A CommonForm 4 ↗
Ben BronsteinDirector2026-06-09A5,30900Derivative, Class A CommonForm 4 ↗
Ben BronsteinDirector2026-06-09A70,00000Derivative, Class A CommonForm 4 ↗
Neal WalkerDirector2026-06-09A3,31800Derivative, Class A CommonForm 4 ↗
Neal WalkerDirector2026-06-09A70,00000Derivative, Class A CommonForm 4 ↗
Gary M. PhillipsDirector2026-06-09A4,97700Derivative, Class A CommonForm 4 ↗
Gary M. PhillipsDirector2026-06-09A6,63600Derivative, Class A CommonForm 4 ↗
Gary M. PhillipsDirector2026-06-09A70,00000Derivative, Class A CommonForm 4 ↗
Richard DouglasDirector2026-06-09A2,32300Derivative, Class A CommonForm 4 ↗
Richard DouglasDirector2026-06-09A19,90900Derivative, Class A CommonForm 4 ↗
Richard DouglasDirector2026-06-09A70,00000Derivative, Class A CommonForm 4 ↗
Michael AlfieriPrincipal Financial Officer2026-11-11A10,00016,500CommonForm 4 ↗
Richard DouglasDirector2026-11-11A200,0001128,900CommonForm 4 ↗
Darlene M. Deptula-HicksDirector2026-11-12A7,50014,875CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

Sources (40 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

  • Section 01, Todd Brady. DEF 14A, filed 2026-04-27. Section “Summary Compensation Table” · page 28. As printed: 4,704,179. View filing ↗
  • Section 01, Stephen Machatha. DEF 14A, filed 2026-04-27. Section “Summary Compensation Table” · page 28. As printed: 1,452,142. View filing ↗
  • Section 01, Michael Alfieri. DEF 14A, filed 2026-04-27. Section “Summary Compensation Table” · page 28. As printed: 245,963. View filing ↗
  • Section 03, Todd Brady OPTION. DEF 14A, filed 2026-04-27. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 03, Stephen Machatha OPTION. DEF 14A, filed 2026-04-27. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 08, Richard H. Douglas, Ph.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 225,216. View filing ↗
  • Section 08, Martin J. Joyce, M.B.A. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 197,719. View filing ↗
  • Section 08, Gary M. Phillips, M.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 196,218. View filing ↗
  • Section 08, Ben R. Bronstein, M.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 192,719. View filing ↗
  • Section 08, Neal S. Walker, D.O. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 177,472. View filing ↗
  • Section 08, Nancy B. Miller-Rich. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 177,472. View filing ↗
  • Section 08, William D. Clark. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 162,459. View filing ↗
  • Section 02, Todd Brady 2026-06-03. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, William D. Clark 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, William D. Clark 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Nancy B. Miller-Rich 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Nancy B. Miller-Rich 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Darlene M. Deptula-Hicks 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Darlene M. Deptula-Hicks 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ben Bronstein 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ben Bronstein 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ben Bronstein 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Neal Walker 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Neal Walker 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Gary M. Phillips 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Gary M. Phillips 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Gary M. Phillips 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Richard Douglas 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Richard Douglas 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Richard Douglas 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Alfieri 2026-11-11. Form 4, filed 2026-11-13. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Richard Douglas 2026-11-11. Form 4, filed 2026-11-13. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Darlene M. Deptula-Hicks 2026-11-12. Form 4, filed 2026-11-16. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 06, 2026 vote. Form 8-K, filed 2026-06-10. Item 5.07 · say-on-pay result. As reported: 80.79% (votes for as printed: 19,477,504). View filing ↗
  • Section 06, 2025 vote. Form 8-K, filed 2025-06-11. Item 5.07 · say-on-pay result. As reported: 69.94% (votes for as printed: 18,847,620). View filing ↗
  • Section 06, 2024 vote. Form 8-K, filed 2024-06-07. Item 5.07 · say-on-pay result. As reported: 91.33% (votes for as printed: 31,493,319). View filing ↗
  • Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
  • Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
  • Section 09b board cost (computed). Computed. Cash 320,222 + equity 0 + all other 0 = 320,222, summed across the director compensation table rows.
  • Aldeyra Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Aldeyra Therapeutics, Inc.'s own proxy. As printed: 4,704,179. View filing ↗
Get the full report — $299